Real‐life experiences with bulevirtide for the treatment of hepatitis delta—48 weeks data from a German centre
Sign Up to like & getrecommendations! Published in 2022 at "Liver International"
DOI: 10.1111/liv.15408
Abstract: In July 2020, the entry inhibitor bulevirtide was approved in the European Union for the treatment of chronic hepatitis delta virus (HDV) infection. We describe the first 48 weeks of bulevirtide therapy in eight patients (n… read more here.
Keywords: real life; experiences bulevirtide; life experiences; hepatitis delta ... See more keywords